vs

Side-by-side financial comparison of ADC Therapeutics SA (ADCT) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $23.1M, roughly 1.2× ADC Therapeutics SA). On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 36.4%).

ADC Telecommunications, Inc. was a communications company in Eden Prairie, Minnesota, a southwest suburb of Minneapolis. It was acquired by TE Connectivity in December 2010 and ceased to exist as a separate entity. ADC products were sold by CommScope after it acquired the Broadband Network Solutions business unit from TE Connectivity in August 2015.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

ADCT vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.2× larger
ZYME
$27.6M
$23.1M
ADCT
Growing faster (revenue YoY)
ZYME
ZYME
+36.2% gap
ZYME
72.6%
36.4%
ADCT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ADCT
ADCT
ZYME
ZYME
Revenue
$23.1M
$27.6M
Net Profit
$-19.6M
Gross Margin
Operating Margin
-77.7%
-80.1%
Net Margin
-71.0%
Revenue YoY
36.4%
72.6%
Net Profit YoY
34.3%
EPS (diluted)
$0.04
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADCT
ADCT
ZYME
ZYME
Q4 25
$23.1M
Q3 25
$15.8M
$27.6M
Q2 25
$18.1M
$48.7M
Q1 25
$17.4M
$27.1M
Q4 24
$16.9M
$31.0M
Q3 24
$18.0M
$16.0M
Q2 24
$17.0M
$19.2M
Q1 24
$17.8M
$10.0M
Net Profit
ADCT
ADCT
ZYME
ZYME
Q4 25
Q3 25
$-41.0M
$-19.6M
Q2 25
$-56.6M
$2.3M
Q1 25
$-38.6M
$-22.6M
Q4 24
$-23.5M
Q3 24
$-44.0M
$-29.9M
Q2 24
$-36.5M
$-37.7M
Q1 24
$-46.6M
$-31.7M
Operating Margin
ADCT
ADCT
ZYME
ZYME
Q4 25
-77.7%
Q3 25
-196.6%
-80.1%
Q2 25
-244.1%
-1.4%
Q1 25
-163.5%
-94.5%
Q4 24
-191.8%
-71.6%
Q3 24
-197.4%
-213.8%
Q2 24
-170.5%
-222.9%
Q1 24
-188.3%
-376.9%
Net Margin
ADCT
ADCT
ZYME
ZYME
Q4 25
Q3 25
-260.1%
-71.0%
Q2 25
-313.2%
4.8%
Q1 25
-221.8%
-83.5%
Q4 24
-75.8%
Q3 24
-244.1%
-186.6%
Q2 24
-214.6%
-195.8%
Q1 24
-261.1%
-315.6%
EPS (diluted)
ADCT
ADCT
ZYME
ZYME
Q4 25
$0.04
Q3 25
$-0.30
$-0.26
Q2 25
$-0.50
$0.03
Q1 25
$-0.36
$-0.30
Q4 24
$-0.26
$-0.32
Q3 24
$-0.42
$-0.39
Q2 24
$-0.38
$-0.49
Q1 24
$-0.56
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADCT
ADCT
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$261.3M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-185.8M
$320.1M
Total Assets
$323.1M
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADCT
ADCT
ZYME
ZYME
Q4 25
$261.3M
Q3 25
$234.7M
$64.8M
Q2 25
$264.6M
$98.3M
Q1 25
$194.7M
$76.2M
Q4 24
$250.9M
$66.1M
Q3 24
$274.3M
$122.4M
Q2 24
$300.1M
$71.0M
Q1 24
$234.3M
$114.8M
Stockholders' Equity
ADCT
ADCT
ZYME
ZYME
Q4 25
$-185.8M
Q3 25
$-238.2M
$320.1M
Q2 25
$-199.2M
$334.5M
Q1 25
$-238.2M
$325.0M
Q4 24
$-202.6M
$338.8M
Q3 24
$-171.9M
$367.0M
Q2 24
$-131.7M
$406.2M
Q1 24
$-194.4M
$438.0M
Total Assets
ADCT
ADCT
ZYME
ZYME
Q4 25
$323.1M
Q3 25
$289.8M
$397.3M
Q2 25
$321.6M
$408.4M
Q1 25
$272.5M
$425.5M
Q4 24
$322.0M
$463.1M
Q3 24
$349.1M
$487.2M
Q2 24
$371.8M
$515.6M
Q1 24
$308.0M
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADCT
ADCT
ZYME
ZYME
Operating Cash FlowLast quarter
$-31.1M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
0.0%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADCT
ADCT
ZYME
ZYME
Q4 25
$-31.1M
Q3 25
$-29.6M
$-31.4M
Q2 25
$-24.1M
$12.1M
Q1 25
$-56.3M
$-3.4M
Q4 24
$-21.9M
$-41.5M
Q3 24
$-25.0M
$-5.9M
Q2 24
$-32.8M
$-25.0M
Q1 24
$-44.1M
$-37.7M
Free Cash Flow
ADCT
ADCT
ZYME
ZYME
Q4 25
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-56.6M
$-3.4M
Q4 24
$-21.9M
$-41.8M
Q3 24
$-25.3M
$-6.8M
Q2 24
$-32.9M
$-25.6M
Q1 24
$-44.6M
$-37.9M
FCF Margin
ADCT
ADCT
ZYME
ZYME
Q4 25
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-325.2%
-12.6%
Q4 24
-129.8%
-134.8%
Q3 24
-140.2%
-42.4%
Q2 24
-193.0%
-133.0%
Q1 24
-250.0%
-377.5%
Capex Intensity
ADCT
ADCT
ZYME
ZYME
Q4 25
0.0%
Q3 25
0.0%
1.5%
Q2 25
0.0%
1.1%
Q1 25
1.5%
0.1%
Q4 24
0.5%
1.0%
Q3 24
1.2%
5.6%
Q2 24
0.2%
3.1%
Q1 24
3.0%
1.8%
Cash Conversion
ADCT
ADCT
ZYME
ZYME
Q4 25
Q3 25
Q2 25
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons